References
- Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345–1350.
- Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153:947–955.
- Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev. 1998;50:357–386.
- Fujii M, Wada A, Tsutamoto T, et al. Bradykinin improves left ventricular diastolic function under long-term angiotensin-converting enzyme inhibition in heart failure. Hypertension. 2002;39:952–957.
- Banerji A, Blumenthal K, Lai K, et al. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5:744–749.
- Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373–388.
- Agah R, Bandi V, Guntupalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med. 1997;23:793–796.
- Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327–332.
- Williams-Johnson JA, Hemmings S, Williams EW, et al. Six years experience of angioedema at the University Hospital of the West Indies. West Indian Med J. 2007; 56:278–281.
- Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–1697.
- Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther. 2002;303:232–237.
- Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088–2089.
- Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides. 2000;34:314–322.
- Bas M, Hoffmann T, Bier H, et al. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol. 2005;59:233–238.
- Chen HM, Liao WS. Differential acute-phase response of rat kininogen genes involves type I and type II interleukin-6 response elements. J Biol Chem. 1993;268:25311–25319.
- McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177–1181.
- Mahmoudpour SH, Leusink M, Van der Putten L, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics. 2013;14:249–260.
- Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8–13.
- Kostis JB, kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637–1642.
- Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624–1630.
- Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10:499–509.
- Vleeming W, Van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Safety. 1998;18:171–188.
- Schiller PI, Messmer SL, Haefeli WE, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy. 1997;52:432–435.
- Kampitak T. Recurrent severe angioedema associated with imidapril and diclofenac. Allergol Int. 2008;57:441–443.
- Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168–1172.
- Stauber T, Confino-Cohen R, Goldberg A. Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors. Am J Rhinol Allergy. 2014;28:54–58.
- Shahzad G, Krsten MA, Blatt C, et al. Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. Mt Sinai J Med. 2006;73:1123–1125.
- Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582–1589.
- Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol. 1997;136:153–158.
- Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967–970.
- Garcia-Pavia P, Tomas JM, Alonso-Pulpon L. Late-onset angioedema due to an angiotensin-converting enzyme inhibitor. Can J Cardiol. 2007;23:315–316.
- Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232.
- Mahmoudpour SH, Asselbergs FW, Terreehorst I, et al. Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. Int J Cardiol. 2015;201:644–645.
- Dyer PD. Late onset angioedema after interruption of angiotensin converting enzyme inhibitor therapy. J Allergy Clin Immunol.1994;93:947–948.
- Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164:910–913.
- Lombardi C, Crivellaro M, Dama A, et al. Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories. Chest. 2005;128:976–979.
- O’Mara NB, O’Mara EM Jr. Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature. Pharacotherapy. 1996;16:675–679.